Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde - 1 Jan 2016

Chaudhary Varun, Brent Michael, Lam Wai-Ching, Devenyi Robert, Teichman Joshua, Mak Michael, Barbosa Joshua, Kaur Harneel, Carter Ronald, Farrokhyar Forough

Abstract excerpt

OBJECTIVE: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). PATIENTS AND METHODS: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Fluorescein Angiography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Fundus Oculi

Share to Intravitreal Injections

Share to Time Factors

Share to Vascular Endothelial Growth Factor A

Share to Wet Macular Degeneration

Source

Identifiers

PMID: 27362858
DOI: 10.1159/000446819

Genes

CFH
ARMS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response.PMID 27362858Read ↗

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Semantic proximity Read ↗

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Semantic proximity Read ↗

Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.Semantic proximity Read ↗

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.Semantic proximity Read ↗

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).Semantic proximity Read ↗

Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors.Semantic proximity Read ↗

Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.Semantic proximity Read ↗

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.Semantic proximity Read ↗

Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.